Search Results - "Duckworth, Edward J"

Oral FXIIa inhibitor KV998086 suppresses FXIIa and single chain FXII mediated kallikrein kinin system activation by Clermont, Allen C, Murugesan, Nivetha, Edwards, Hannah J, Lee, Daniel K, Bayliss, Natasha P, Duckworth, Edward J, Pethen, Stephen J, Hampton, Sally L, Gailani, David, Feener, Edward P

“…The kallikrein kinin system (KKS) is an established pharmacological target for the treatment and prevention of attacks in hereditary angioedema (HAE)…”
Get full text

Pharmacological suppression of the kallikrein kinin system with KVD900: An orally available plasma kallikrein inhibitor for the on‐demand treatment of hereditary angioedema by Duckworth, Edward J., Murugesan, Nivetha, Li, Lily, Rushbrooke, Louise J., Lee, Daniel K., De Donatis, Gian Marco, Maetzel, Andreas, Yea, Christopher M., Hampton, Sally L., Feener, Edward P.

“…Background Hereditary angioedema (HAE) is a rare genetic disease that leads to recurrent episodes of swelling and pain caused by uncontrolled plasma kallikrein…”
Get full text

KVD900, an oral on-demand treatment for hereditary angioedema: Phase 1 study results by Maetzel, Andreas, Smith, Michael D., Duckworth, Edward J., Hampton, Sally L., De Donatis, Gian Marco, Murugesan, Nivetha, Rushbrooke, Louise J., Li, Lily, Francombe, Danielle, Feener, Edward P., Yea, Christopher M.

“…Attacks of hereditary angioedema are attributed to excessive plasma kallikrein (PKa) activity, which cleaves high-molecular-weight kininogen to generate the…”
Get full text